{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:49:58Z","timestamp":1792633798373,"version":"4.5.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Virus vectored genetic vaccines (Vvgv) represent a promising approach for eliciting immune protection against infectious diseases and cancer. However, at variance with classical vaccines to date, no adjuvant has been combined with clinically approved genetic vaccines, possibly due to the detrimental effect of the adjuvant-induced innate response on the expression driven by the genetic vaccine vector. We reasoned that a potential novel approach to develop adjuvants for genetic vaccines would be to \u201csynchronize\u201d in time and space the activity of the adjuvant with that of the vaccine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To this aim, we generated an Adenovirus vector encoding a murine anti-CTLA-4 monoclonal antibody (Ad-9D9) as a genetic adjuvant for Adenovirus based vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The co-delivery of Ad-9D9 with an Adeno-based COVID-19 vaccine encoding the Spike protein resulted in stronger cellular and humoral immune responses. In contrast, only a modest adjuvant effect was achieved when combining the vaccine with the same anti-CTLA-4 in its proteinaceous form. Importantly, the administration of the adjuvant vector at different sites of the vaccine vector abrogates the immunostimulatory effect. We showed that the adjuvant activity of Ad-\u03b1-CTLA-4 is independent from the vaccine antigen as it improved the immune response and efficacy of an Adenovirus based polyepitope vaccine encoding tumor neoantigens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our study demonstrated that the combination of Adenovirus Encoded Adjuvant (AdEnA) with an Adeno-encoded antigen vaccine enhances immune responses to viral and tumor antigens, representing a potent approach to develop more effective genetic vaccines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1156714","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T01:53:15Z","timestamp":1682473995000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer"],"prefix":"10.3389","volume":"14","author":[{"given":"Anna Morena","family":"D\u2019Alise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Nocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Garzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Secl\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigia","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvia","family":"Troise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Cotugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Allocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Lahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Sasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Scarselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Nicosia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.635337","article-title":"Developmental landscape of potential vaccine candidates based on viral vector for prophylaxis of COVID-19","volume":"8","author":"Bezbaruah","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B3","doi-asserted-by":"publisher","first-page":"103336","DOI":"10.1016\/j.drudis.2022.08.004","article-title":"The current status of COVID-19 vaccines","volume":"27","author":"Rueda-Fernandez","year":"2022","journal-title":"A scoping review. Drug Discov Today"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10071450","article-title":"Viral vector vaccine development and application during the COVID-19 pandemic","volume":"10","author":"Deng","year":"2022","journal-title":"Microorganisms"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7020042","article-title":"Designed DNA-encoded IL-36 gamma acts as a potent molecular adjuvant enhancing zika synthetic DNA vaccine-induced immunity and protection in a lethal challenge model","volume":"7","author":"Louis","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.03.086","article-title":"Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model","volume":"33","author":"Villarreal","year":"2015","journal-title":"Vaccine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00327","article-title":"Adjuvant screen identifies synthetic DNA-encoding Flt3L and CD80 immunotherapeutics as candidates for enhancing anti-tumor T cell responses","volume":"11","author":"Thorne","year":"2020","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.07.066","article-title":"Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model","volume":"28","author":"Sorensen","year":"2010","journal-title":"Vaccine"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003480","article-title":"Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and treg depletion","volume":"9","author":"D\u2019Alise GL","year":"2021","journal-title":"J ImmunoTherapy Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1016791108","article-title":"Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance","volume":"108","author":"Pedicord","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201403876","article-title":"Vaccines for the 21st century","volume":"6","author":"Delany","year":"2014","journal-title":"EMBO Mol Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.04.055","article-title":"Vaccine adjuvants: understanding the structure and mechanism of adjuvanticity","volume":"37","author":"Shi","year":"2019","journal-title":"Vaccine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78280","article-title":"Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling","volume":"125","author":"Quinn","year":"2015","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.21775\/cimb.022.017","article-title":"Molecular adjuvants for DNA vaccines","volume":"22","author":"Li","year":"2017","journal-title":"Curr Issues Mol Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.2.183","article-title":"Protective immunity to nematode infection is induced by CTLA-4 blockade","volume":"186","author":"McCoy","year":"1997","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.8.3786-3792.1999","article-title":"CTLA-4 blockade enhances the immune response induced by mycobacterial infection but does not lead to increased protection","volume":"67","author":"Kirman","year":"1999","journal-title":"Infect Immun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","article-title":"Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells","volume":"1","author":"Selby","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.12.005","article-title":"The coinhibitory receptor CTLA-4 controls b cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells","volume":"41","author":"Sage","year":"2014","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191926","article-title":"Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody","volume":"13","author":"Gombos","year":"2018","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1038\/s41467-019-10594-2","article-title":"Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade","volume":"10","author":"D'Alise","year":"2019","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1429","article-title":"Synthetic DNA-encoded monoclonal antibody delivery of anti-CTLA-4 antibodies induces tumor shrinkage in vivo","volume":"78","author":"Duperret","year":"2018","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.4.1688-1699.2006","article-title":"A novel adenovirus type 6 (Ad6)-based hepatitis c virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques","volume":"80","author":"Capone","year":"2006","journal-title":"J Virol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1376154","article-title":"Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model","volume":"7","author":"Field","year":"2017","journal-title":"Oncoimmunology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/nyas.14049","article-title":"Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4(+) effector T cell infiltration into murine pancreatic tumors","volume":"1445","author":"Zaidi","year":"2019","journal-title":"Ann N Y Acad Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo7604","article-title":"Adenoviral-based vaccine promotes neoantigen-specific CD8(+) T cell stemness and tumor rejection","volume":"14","author":"D'Alise","year":"2022","journal-title":"Sci Transl Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01937-6","article-title":"Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results","volume":"28","author":"Palmer","year":"2022","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat Rev Drug Discov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1156714\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T01:53:18Z","timestamp":1682473998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1156714\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2023.1156714"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1156714","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"article-number":"1156714"}}